Valneva SE (VALN) Research & Development (2021 - 2026)

Valneva SE (VALN) posted quarterly Research & Development of -$17.3 million for Q1 2026, down 1.75% year-on-year from -$17.6 million in Q1 2025, and down 110.49% on a QoQ basis from $165.0 million in Q4 2025.

Valneva SE (VALN) Research & Development (2021 - 2026) Analysis & Trends

Valneva SE (VALN) has reported Research & Development for 6 consecutive years, with -$17.3 million the latest figure, recorded in Q1 2026.

  • Quarterly Research & Development fell 1.75% year-over-year to -$17.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.8 million (up 17.59% YoY) and the FY2025 annual result came in at $97.1 million, up 15.05% from the prior year.
  • Research & Development declined to -$17.3 million in Q1 2026 per VALN's latest filing, from $165.0 million in the prior quarter.
  • Over the last five years, Research & Development for VALN reached as high as $205.2 million in Q4 2022 and fell as low as -$35.5 million in Q2 2022.
  • A 5-year average of $20.7 million and a median of -$17.3 million in 2026 frame the typical range for Research & Development.
  • Annual changes were most pronounced in 2023 — Research & Development surged 61.81% — and 2025, when it slumped 44.5%.
  • Year by year, Research & Development stood at $205.2 million in 2022, then slumped by 43.37% to $116.2 million in 2023, then advanced by 20.17% to $139.6 million in 2024, then climbed by 18.19% to $165.0 million in 2025, then sank by 110.49% to -$17.3 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods registered -$17.3 million, $165.0 million, and -$31.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -17.94 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 541.22 Mn
4 NuCana 279.75 Bn 279.75 Bn - -2.31 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 961.60 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.54 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 15.66 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.37 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 343.97 Mn
10 Valneva SE 803.90 Mn 680.66 Mn 5.38 Mn -17.31 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.31 Mn
Dec 31, 2025 165.04 Mn
Sep 30, 2025 -31.05 Mn
Jun 30, 2025 -19.90 Mn
Mar 31, 2025 -17.02 Mn
Dec 31, 2024 139.64 Mn
Sep 30, 2024 -21.49 Mn
Jun 30, 2024 -18.84 Mn
Mar 31, 2024 -14.94 Mn
Dec 31, 2023 116.20 Mn
Sep 30, 2023 -18.48 Mn
Jun 30, 2023 -13.56 Mn
Mar 31, 2023 -16.01 Mn
Dec 31, 2022 205.18 Mn
Sep 30, 2022 -26.74 Mn
Jun 30, 2022 -35.50 Mn
Mar 31, 2022 -23.54 Mn
Dec 31, 2021 330.60 Mn
Sep 30, 2021 -43.81 Mn
Jun 30, 2021 -58.04 Mn